Afficher la couverture '3-years follow-up of double-blind randomized phase II comparing concurrent high-dose cisplatin chemo-radiation plus xevinapant or placebo in high-risk patients with locally advanced squamous cell carcinoma of the head and neck | Bourhis, J.' en grand format
/5

0 avis

3-years follow-up of double-blind randomized phase II comparing concurrent high-dose cisplatin chemo-radiation plus xevinapant or placebo in high-risk patients with locally advanced squamous cell carcinoma of the head and neck

Archive ouverte

Bourhis, J. | Sun, X. | Le Tourneau, C. | Pointreau, Y. | Sire, C. | Kaminsky-Forrett, M-C. | Coutte, Alexandre | Alfonsi, M. | Boisselier, P. | Martin, L. | Delord, J-P. | Clatot, F. | Biau, J. | Rolland, F. | Gollmer, K. | Szyldergemajn, S. A. | Even, C. | Tao, Y.

Edité par CCSD ; Elsevier -

ESMO Virtual Congress, ELECTR NETWORK, SEP 19-OCT 18, 2020. International audience

Consulter en ligne

Suggestions

Du même auteur

Double-blind randomized phase II results comparing concurrent high-dose cisplatin chemorradiation (CRT) plus debio 1143 or placebo in high-risk patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN): A GORTEC study

Archive ouverte | Bourhis, J. | CCSD

44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, SEP 27-OCT 01, 2019. International audience

LBA33 5-year overall survival (OS) in patients (pts) with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) treated with xevinapant + chemoradiotherapy (CRT) vs placebo + CRT in a randomized, phase II study

Archive ouverte | Bourhis, J. | CCSD

International audience. BackgroundIn a double-blind, randomized, phase 2 study of pts with unresected LA SCCHN (NCT02022098), xevinapant + standard-of-care (SOC) CRT significantly improved locoregional control at 18...

854MO Avelumab-cetuximab-radiotherapy (RT) versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Final analysis of randomized phase III GORTEC 2017-01 REACH trial

Archive ouverte | Tao, Y. | CCSD

International audience. BackgroundBased on a potential synergistic effect of anti–PD-L1 avelumab plus cetuximab and RT, this combination was tested in a randomized trial against two standards of care (SOC) in LA-SCC...

Chargement des enrichissements...